These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [A case responding to weekly paclitaxel therapy as second-line chemotherapy for gastric cancer previously treated with TS-1].
    Author: Imamura H, Furukawa H, Kishi K, Tatsuta M, Masutani S, Fukunaga M, Nakayama T, Shimizu J, Takemoto H, Kishimoto T, Kato H, Yamamoto K, Fujishima M, Kawasaki T.
    Journal: Gan To Kagaku Ryoho; 2004 Oct; 31(11):1693-5. PubMed ID: 15553685.
    Abstract:
    A 58-year-old male patient with the recurrence of para-aortic lymphnodes after TS-1 treatment was treated by a weekly infusion of paclitaxel as second-line chemotherapy. Paclitaxel was administered at a weekly dose of 70 mg/m2/day for three weeks followed by a one week interval. After 2 courses, the tumor was reduced, and the reduction was judged as PR. Moreover, after 5 courses, the tumor was more remarkably reduced and the reduction was judged as CR. The grade 2 leukopenia, neutropenia, and grade 1 alopecia were observed as adverse events. Recently, we treated 11 patients of advanced or recurrent gastric cancers with measurable lesions, using the weekly paclitaxel therapy after TS-1 treatment. The response rate was 36.4%. The median duration of PR was 130 days. Therefore, a weekly paclitaxel regimen was considered to be one of the promising regimens for advanced or recurrent gastric cancer as the second-line chemotherapy after TS-1 treatment.
    [Abstract] [Full Text] [Related] [New Search]